The goal of this study was to validate this hypothesis and identify mechanisms by which clinically relevant Src inhibitors prevent MCL-1 accumulation by MCL-1 antagonists, and enhance anti-AML activity. Here, MCL1 is linked to acute myeloid leukemia.